Skip to main content

Evommune, Inc.

corporate_fare Company Profile

Evommune, Inc.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Exchange: NYSESector: Life Sciences

show_chartPrice Chart

Loading chart...

feed EVMN - Latest Insights

EVMN
Apr 24, 2026, 4:23 PM EDT
Filing Type: 424B3
Importance Score:
7
Resale Registration Filed for 4.5 Million Shares from Private Placement
Sentiment: Negative
View Wiseek Article
EVMN
Apr 21, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Evommune Secures $125.3M in Private Placement to Fund Clinical Programs
Sentiment: Positive
View Wiseek Article
EVMN
Apr 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Evommune Details Phase 2b Trial for EVO756 in Migraine Prophylaxis
Sentiment: Positive
View Wiseek Article
EVMN
Mar 05, 2026, 4:07 PM EST
Filing Type: 10-K
Importance Score:
9
Evommune Reports Positive Phase 2a EVO301 Data, Secures $125M Financing, Extends Cash Runway to H2 2028
Sentiment: Positive
View Wiseek Article
EVMN
Mar 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Evommune Secures $125M Private Placement, Extends Cash Runway Through 2028
Sentiment: Positive
View Wiseek Article
EVMN
Mar 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Evommune's EVO301 Hits Primary Endpoint in Phase 2a AD Trial, Secures $125M Private Placement
Sentiment: Positive
View Wiseek Article
EVMN
Feb 19, 2026, 4:30 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Institutional Investor LSP 7 Increases Stake in Evommune, Inc. by $10 Million
Sentiment: Positive
View Wiseek Article
EVMN
Feb 17, 2026, 7:28 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
RA Capital Management Boosts Evommune Stake to 9.7% via $1M Private Placement Purchase
Sentiment: Positive
View Wiseek Article
EVMN
Feb 13, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Evommune Secures $125M Private Placement Following Positive Phase 2a Trial Results
Sentiment: Positive
View Wiseek Article
EVMN
Feb 10, 2026, 8:28 AM EST
Filing Type: 8-K
Importance Score:
9
Evommune Announces Highly Positive Phase 2a Data for EVO301 in Atopic Dermatitis
Sentiment: Positive
View Wiseek Article